April 22, 2024

bioRN M2M Member to Member featuring Nanobot

bioRN M2M Member to Member featuring Nanobot
Go back

Nanobot OÜ Communication is an award-winning scientific communication agency specializing in marketing and communication strategies for life science companies. They offer services in strategic content creation, targeted marketing, and design to ensure scientific breakthroughs are well-represented and effectively communicated. Nanobot excels in creating engaging digital content, effective slide decks, and impactful presentations and booth materials for scientific events.

register now

Our latest News

discover more
Green hydrogen for a climate-neutral industry: InnovationLab organizes Clean Tech Innovation Day

Green hydrogen for a climate-neutral industry: InnovationLab organizes Clean Tech Innovation Day

Heidelberg, Germany, November 6, 2024 – The technology transfer platform InnovationLab is looking forward to the premiere of a new event format: hydrogen experts from Germany and abroad are expected to attend the Clean Tech Innovation Day on Monday, November 11 (9 a.m. to 6 p.m.). Together with its two co-partners, the Rhine-Neckar metropolitan region […]

read more
New findings on cell types and their interactions in multiple sclerosis

New findings on cell types and their interactions in multiple sclerosis

An international research team led by Professor Dr. Lucas Schirmer and Professor Dr. Julio Saez-Rodriguez from the Medical Faculties of Heidelberg University, in Mannheim and Heidelberg, has studied the different cell types in so-called subcortical lesions, tissue damage to deep brain structures, at different stages of multiple sclerosis (MS) and investigated how they communicate. In […]

read more
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Partnership to Combine AbbVie’s Oncology Expertise with EvolveImmune’s Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies, today announced a collaboration […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp